medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 2

<< Back Next >>

Gac Med Mex 2003; 139 (2)

Hematology Experience In Mexico
br>I. Introduction.
II. Implementation of the Umbilical Cord Blood Bank.
III. NAT for Detection of Hepatitis C and HIV at the National Institute of Pediatrics in Mexico City.
IV. Economic Evaluation of Hemophili

Silva-López S, Ambriz-Fernández R, Escamilla-Guerrero G, Quintana-González S, Martínez-Murillo C, Benitez-Aranda H, Berges A, Collazo-Jaloma J, Esparza-Flores A, Pompa-Garza T, Taboada C, Zavala-Cervantes S, Gómez-Almaguer D

Language: Spanish
References: 50
Page: 69-80
PDF size: 121.91 Kb.


Text Extraction

No abstract


REFERENCES

  1. MJ Laughlin. Umbilical cord blood for allogeneic transplantation in children and adults, Bone Marrow Transplantation (2001)27;1-6.

  2. Larry C, Rebecca Haley, Karen Ballen. In utero or ex utero cord blood collection: wich is better. TRANSFUSION (2002)42:1261-1267.

  3. Dorothy E Vawter, Gayl Rogers-Chrysler, Mary Clay, Larrie Pitttelko, Dave Therkelsen, Debora Kim, Jefrey Mc Cullough. A phased consent policy cord blood donation. TRANSFUSION (2002)42;1268-1274.

  4. Karen Ballen, Hal E. Broxmeyer, Jeffrey McCullough, Wanda Piaciabello, Paolo Rebulla, Catherine M. Verfaillie, John E. Wagner. Current Status of Cord Blood Banking and Transplantation in the United States and Europe. Biology of Blood and Marrow Transplantation (2001)7;635-645.

  5. Guide to the preparation use and quality assurance of blood components Council of Europe Publishing. 8th edition, chapter 24; pp197-203.

  6. Flanagan P, Barbara J. PCR Testing of Plasma Pools from concept to Reality Transfusion Medicine Review, 1999;13(3):164-176.

  7. Barker J N, Weisdorf DJ, DeFor TE, et al. Multiple unit unrelated donor umbilical cord blood transplantation in high risk adults with hematologic malignancies: Impact of engrafment and chimerism. Blood 2002;100 ( suppl 1) Abstract 142.

  8. Ambriz FR. Experiencia del trasplante de células hematopoyéticas de sangre periférica en el Banco Central de Sangre, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Gac Méd Méx 2002;138(supl 1)29-30.

  9. Gómez ME. ¿ Como lograr el efecto centro ? Experiencia en trasplante de células hematopoyéticas. Gac Méd Méx 2002;138(supl 1):135-136.

  10. Indrikovs AJ. Trasplante de células progenitoras de sangre de cordón umbilical. Gac Méd Méx 2002;138(supl 1):130-132.

  11. Girolomoni G, Ricciardi-Castagnoli P. Dentritic cells hold promise for immunotherapy. Immunolo Today 1997;18:102-104.

  12. Programa de Acción: Transfusión Sanguínea. Primera Edición año 2002, Secretaría de Salud. Gobierno de México.

  13. Engavall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA): quantitative assay of immunoglobulin G. Immunmochemistry, 1971;8:871-875.

  14. Hawkes R, Nidal E, Gordon J. A dot-immunobinding assay or monoclonal and other antibodies. Anal Biochem 1982;119:142-144.

  15. Herbrink P, van Bussel FJ, Warnaar SO. The antigen spot test: a highly sensitive assay for the detection of antibodies. J. immunol Methods 1982; 48:293-297.

  16. Towbin H, Gordon J. Immunoblotting and dot-immunobinding current status and outlook. J. Immunol Methods º984; 72:313-319.

  17. Towbin H. Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets : procedure and some applications. Proc Natl Acad Sci U S A 1979,76;204-208.

  18. Gallarda JL, Dragon E. Blood Sreening by Nucleic Acid Amplification Technology: Current Issues, Future Challenges. Mol Diag 2000;5(1)11-22.

  19. Schreiber GB, Busch MP, Kleinman SH, Koretitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donors Study. N. Engl J Med 1996;334:1685-1690.

  20. Flanagan P, Barbara J. PCR Testing of plasma pools: From concept to Reality. Trans Med Rev.1999; 13:164-176.

  21. Castro FJ, Suleda S, Esteban JI, Viladomiu L, Martell M, Dragon E, Esteban R, Guardia J. Evaluation of hepatitis Cvirus RNA RT/PCR qualitative and quantitative second generation assays. J. Virol Met 2001;91:51-58.

  22. Zebala JA, Barany F. Implications for the ligase chain reaction in gastroenterology .J. Clin Gastroenterol 1993;17(2)171-174.

  23. Flanagan P,Barbara J. PCR Testing of Plasma Pools: From Concept to Reality. Transf Med Rev 1999;13(3):164-176.

  24. Martínez-Murillo C, Quintana GS, Ambriz FR, Kasper C. Hemofilia. D.F., México: Editorial Prado; 2000.

  25. Antunes SV. Haemophilia in the developing world: the Brazilian experience. Hemophilia 2002; 8:199-204.

  26. Martínez-Murillo C, Quintana González S, Ambriz FR. Hemofilia A y B. En Martínez-Murillo C, Ambriz FR, Quintana González S. Tópicos Selectos de Medicina Transfusional. D.F., México: Editorial Prado; 2002.p. :201-216.

  27. Kasper CK. Concentrate safety and efficacy. Haemophilia (2002);8:161–165.

  28. Quintana González S, Martínez-Murillo C, Osornio Mejía A, Ambriz FR. Programa de tratamiento en casa. En Martínez-Murillo C, Ambriz FR, Quintana González S. Tópicos Selectos de Medicina Transfusional. D.F., México: Editorial Prado; 2002.p.:239-247.

  29. Ekert H, Moorehead M, Williamson G. Home treatment of haemophilia. A follow-up study. Med J Aust 1981;2(1):21-23.

  30. Szucs T, Öffner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia 1996;2:211-217.

  31. Guenthner EE, Hilgartner MW, Miller CH, Vienne G. Hemophilic arthropathy: effect of home care on treatment patterns and joint disease. J Pediatr 1980;97(3):378-382.

  32. Molho P, Rolland N, Lebrun T, Dirat G, Courpied JP, Croughs T et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study. Haemophilia 2000;6(1):23-32.

  33. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. Int J Technol Assess Health Care 1995;11(2):327-344.

  34. Astermark J. Approaches to funding: Swedish cost-effectiveness study. Haemophilia 1998;4(Suppl 1):10-12.

  35. P. Isarangkura P. Haemophilia care in the developing world: benchmarking for excellence. Haemophilia (2002);8:205-210.

  36. Mannucci MP, Tuddenham GD. The Hemophilias: progress and problems. Sem Hematol 1999;4:104-117.

  37. Aledort LM. Unsolved problems in haemophilia. Haemophilia 1998;4:341-345.

  38. Evatt BL, Austin H, Leon G, Ruiz Sáez A, de Bosch N. Hemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. Haemophilia 1999; 5:295-300.

  39. Berntorp E. Progress in haemophilic care: ethical issues. Haemophilia (2002);8:435–438.

  40. Szucs T, Öffner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia 1996;2:211-217.

  41. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. Int J Technol Assess Health Care 1995;11(2):327-344.

  42. Astermark J. Approaches to funding: Swedish cost-effectiveness study. Haemophilia 1998; 4(Suppl 1):10-12.

  43. Pettersson H. Radiographic Scores and Implication. Seminar in Hematology 1993;30(2):7-9.

  44. Drummond MF, Richardson S, O’Brien BJ, Levine M, Heyland D. for the Evidence-Based Medicine Working Group. Users’ Guides to the Medical Literature. XIII How to use an article on economic analysis of clinical practice. JAMA 1997;19:1552-1557.

  45. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2201;411:385-389.

  46. Tiberghein P. Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation . J Intern Med.2001;249:369-377.

  47. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med. 1989;320:828,834.

  48. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.

  49. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol. 1999;135 (1):26-32.

  50. van Doorn R, van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000; 136 (4):504-510).




2020     |     www.medigraphic.com